首页> 美国卫生研究院文献>Oncology Letters >Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells
【2h】

Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells

机译:API-1和FR180204对人DLD-1和LoVo结直肠癌细胞增殖和凋亡的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The activation of the phosphatidylinositol-3 kinase/v-akt murine thymoma viral oncogene homolog (Akt) and mitogen activated protein kinase kinase/extracellular signal-regulated kinase (ERK) pathways are implicated in the majority of cancers. Selective inhibition of Akt and ERK represents a potential approach for cancer therapy. Therefore, the present study aimed to investigate the apoptotic and anti-proliferative effects of the novel and selective Akt inhibitor 4-amino-5,8-dihydro-5-oxo-8-β-D-ribofuranosyl-pyrido[2,3-d]pyrimidine-6-carboxamide (API-1) and selective ERK1/2 inhibitor (FR) alone and in combination on colorectal cancer (CRC) cells (DLD-1 and LoVo). In addition, the effects of API-1 and FR on Akt and ERK signaling pathways were also investigated. The effects of the agents on DLD-1 and LoVo cells were evaluated in terms of cell viability, cytotoxicity, DNA synthesis rate, DNA fragmentation and caspase-3 activity levels. In addition, quantitative reverse transcription-polymerase chain reaction and western blot analysis were performed to examine relevant mRNA and protein levels. The present study observed that the combination of FR with API-1 resulted in significant apoptosis and cytotoxicity compared with any single agent alone in a time-dependent manner in these cells. Also, treatment with FR and API-1 in combination decreased the expression levels of B-cell lymphoma-2 (BCL2), Bcl-2-like1, cyclin D1 and cMYC, and increased the expression levels of BCL2-associated X protein and BCL2 antagonist/killer via phosphorylated Akt and phosphorylated ERK1/2 downregulation. The combination of Akt and ERK1/2 inhibitors resulted in enhanced apoptotic and anti-proliferative effects against CRC cells. The present study hypothesizes that the combination of FR and API-1 in CRC cells may contribute toward potential anti-carcinogenic effects. Additional analyses using other cancer cell lines and animal models are required to confirm these findings in vitro and in vivo.
机译:磷脂酰肌醇3激酶/ v-akt鼠胸腺瘤病毒癌基因同源物(Akt)和有丝分裂原活化的蛋白激酶激酶/细胞外信号调节激酶(ERK)途径的激活与大多数癌症有关。 Akt和ERK的选择性抑制代表了一种潜在的癌症治疗方法。因此,本研究旨在研究新型选择性Akt抑制剂4-氨基-5,8-二氢-5-氧代-8-β-D-呋喃呋喃糖基-吡啶基[2,3-]的凋亡和抗增殖作用。 d]嘧啶-6-羧酰胺(API-1)和选择性ERK1 / 2抑制剂(FR)单独使用或联合使用对大肠癌细胞(CRC)(DLD-1和LoVo)的影响。此外,还研究了API-1和FR对Akt和ERK信号通路的影响。根据细胞活力,细胞毒性,DNA合成速率,DNA片段化和caspase-3活性水平评估了这些试剂对DLD-1和LoVo细胞的作用。另外,进行定量逆转录-聚合酶链反应和蛋白质印迹分析以检查相关的mRNA和蛋白质水平。本研究发现,与这些单独的单一药物相比,FR与API-1的组合在这些细胞中导致了明显的凋亡和细胞毒性。此外,FR和API-1联合治疗可降低B细胞淋巴瘤2(BCL2),Bcl-2-like1,cyclin D1和cMYC的表达水平,并增加与BCL2相关的X蛋白和BCL2的表达水平磷酸化的Akt和磷酸化的ERK1 / 2的下调可以拮抗拮抗剂/杀手。 Akt和ERK1 / 2抑制剂的组合可增强针对CRC细胞的凋亡和抗增殖作用。本研究假设CRC细胞中FR和API-1的组合可能有助于潜在的抗癌作用。需要使用其他癌细胞系和动物模型进行其他分析,以在体外和体内确认这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号